Kenneth Bartley

Array ( [id] => 20163835 [patent_doc_number] => 20250255881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => Cancer Treatment [patent_app_type] => utility [patent_app_number] => 19/194136 [patent_app_country] => US [patent_app_date] => 2025-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19194136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402206 [patent_doc_number] => 12492174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases [patent_app_type] => utility [patent_app_number] => 19/042986 [patent_app_country] => US [patent_app_date] => 2025-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29739 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19042986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19940213 [patent_doc_number] => 12312335 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-05-27 [patent_title] => Crystalline pharmaceutically acceptable salt and polymorphic form of the glutaminyl cyclase inhibitor Varoglutamstat [patent_app_type] => utility [patent_app_number] => 19/020776 [patent_app_country] => US [patent_app_date] => 2025-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 32 [patent_no_of_words] => 20260 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19020776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613048 [patent_doc_number] => 20240398728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => STERILE TOPICAL SALINE PUTRESCINE FORMULATION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/805683 [patent_app_country] => US [patent_app_date] => 2024-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8507 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18805683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556293 [patent_doc_number] => 20240368085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST [patent_app_type] => utility [patent_app_number] => 18/772244 [patent_app_country] => US [patent_app_date] => 2024-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13439 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18772244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213554 [patent_doc_number] => 12410196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Benzopyrimidine compounds and use thereof [patent_app_type] => utility [patent_app_number] => 18/768367 [patent_app_country] => US [patent_app_date] => 2024-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38506 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18768367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19922913 [patent_doc_number] => 12297183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Heteroaryl azole compound and pest control agent [patent_app_type] => utility [patent_app_number] => 18/743634 [patent_app_country] => US [patent_app_date] => 2024-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17107 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 389 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18743634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19649983 [patent_doc_number] => 12171743 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Forms of aticaprant [patent_app_type] => utility [patent_app_number] => 18/679720 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 33621 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18679720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403596 [patent_doc_number] => 20240287107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF [patent_app_type] => utility [patent_app_number] => 18/541172 [patent_app_country] => US [patent_app_date] => 2024-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19701440 [patent_doc_number] => 12195449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof [patent_app_type] => utility [patent_app_number] => 18/650207 [patent_app_country] => US [patent_app_date] => 2024-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35908 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343487 [patent_doc_number] => 20240252450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => TREATMENT FOR EPILEPTIC SEIZURES [patent_app_type] => utility [patent_app_number] => 18/630615 [patent_app_country] => US [patent_app_date] => 2024-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18630615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448837 [patent_doc_number] => 20240308967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => HIGHLY PURE PHENTOLAMINE MESYLATE AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 18/619535 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18619535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462398 [patent_doc_number] => 20240316067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => METHODS OF DECREASING HEPARAN SULFATE EXPRESSION USING EXT1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/593135 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318242 [patent_doc_number] => 20240239784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => INDOLE COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/593643 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19536705 [patent_doc_number] => 12129246 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-29 [patent_title] => Hydroquinazoline derivatives for the treatment of a disease or disorder [patent_app_type] => utility [patent_app_number] => 18/589841 [patent_app_country] => US [patent_app_date] => 2024-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41436 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18589841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19477367 [patent_doc_number] => 20240325409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => Fused Heterotetracyclic Antiviral Agents [patent_app_type] => utility [patent_app_number] => 18/587048 [patent_app_country] => US [patent_app_date] => 2024-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26694 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 821 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18587048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20178225 [patent_doc_number] => 20250262183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => Antibiotic Topical Composition for Absorption into Systemic Bloodstream [patent_app_type] => utility [patent_app_number] => 18/581002 [patent_app_country] => US [patent_app_date] => 2024-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127843 [patent_doc_number] => 12370143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Compound or salt thereof and lipid particles [patent_app_type] => utility [patent_app_number] => 18/443959 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37474 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 401 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143904 [patent_doc_number] => 12378231 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof [patent_app_type] => utility [patent_app_number] => 18/440166 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50957 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 424 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387798 [patent_doc_number] => 20240277668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS [patent_app_type] => utility [patent_app_number] => 18/425829 [patent_app_country] => US [patent_app_date] => 2024-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18425829 [rel_patent_id] =>[rel_patent_doc_number] =>)